TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,089 JPY | -0.02% |
|
+0.49% | +0.86% |
| 26/04 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
| 26/04 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 70,29,161 | 51,53,364 | 62,29,971 | 54,23,454 | 67,62,204 | 64,15,371 | - | - |
| Enterprise Value (EV) 1 | 1,20,54,743 | 96,09,054 | 98,62,522 | 89,19,170 | 1,06,11,015 | 1,01,86,084 | 98,53,178 | 95,41,050 |
| P/E ratio | 40 x | 118 x | 16.6 x | 23.8 x | 21.3 x | 46.4 x | 27.6 x | 22.5 x |
| Yield | 3.98% | 5.44% | 4.52% | 5.15% | 4.14% | 4.6% | 4.64% | 4.72% |
| Capitalization / Revenue | 3.35 x | 1.57 x | 1.95 x | 1.52 x | 1.68 x | 1.56 x | 1.59 x | 1.56 x |
| EV / Revenue | 5.75 x | 2.92 x | 3.08 x | 2.5 x | 2.63 x | 2.48 x | 2.45 x | 2.32 x |
| EV / EBITDA | 25.3 x | 14 x | 9.23 x | 8.54 x | 9.19 x | 9.74 x | 8.98 x | 8.27 x |
| EV / FCF | -4.81 x | 9.99 x | 16 x | 8.92 x | 28.7 x | 29.5 x | 14.6 x | 14.4 x |
| FCF Yield | -20.8% | 10% | 6.26% | 11.2% | 3.49% | 3.39% | 6.86% | 6.97% |
| Price to Book | 1.36 x | 1.09 x | 1.2 x | 0.95 x | 1.06 x | 1.01 x | 1.02 x | 1.01 x |
| Nbr of stocks (in thousands) | 15,54,780 | 15,57,849 | 15,63,355 | 15,50,444 | 15,54,530 | 15,68,934 | - | - |
| Reference price 2 | 4,521 | 3,308 | 3,985 | 3,498 | 4,350 | 4,089 | 4,089 | 4,089 |
| Announcement Date | 14/05/19 | 13/05/20 | 11/05/21 | 11/05/22 | 11/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20,97,200 | 32,91,200 | 31,97,812 | 35,69,006 | 40,27,478 | 40,99,317 | 40,28,429 | 41,07,599 |
| EBITDA 1 | 4,77,415 | 6,84,057 | 10,68,940 | 10,43,995 | 11,54,905 | 10,46,202 | 10,97,806 | 11,53,436 |
| EBIT 1 | 2,05,000 | 1,00,400 | 5,09,269 | 4,60,844 | 4,90,505 | 2,67,999 | 4,29,150 | 4,89,383 |
| Operating Margin | 9.77% | 3.05% | 15.93% | 12.91% | 12.18% | 6.54% | 10.65% | 11.91% |
| Earnings before Tax (EBT) 1 | 94,896 | -60,754 | 3,66,235 | 3,02,571 | 3,75,090 | 1,32,641 | 3,14,185 | 3,87,676 |
| Net income 1 | 1,09,100 | 44,200 | 3,76,005 | 2,30,059 | 3,17,017 | 1,34,022 | 2,33,930 | 2,91,583 |
| Net margin | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.27% | 5.81% | 7.1% |
| EPS 2 | 113.0 | 28.00 | 240.7 | 147.1 | 204.3 | 88.13 | 148.1 | 182.1 |
| Free Cash Flow 1 | -25,07,219 | 9,61,871 | 6,17,401 | 9,99,853 | 3,70,054 | 3,44,948 | 6,75,738 | 6,64,805 |
| FCF margin | -119.55% | 29.23% | 19.31% | 28.01% | 9.19% | 8.41% | 16.77% | 16.18% |
| FCF Conversion (EBITDA) | - | 140.61% | 57.76% | 95.77% | 32.04% | 32.97% | 61.55% | 57.64% |
| FCF Conversion (Net income) | - | 2,176.18% | 164.2% | 434.61% | 116.73% | 257.38% | 288.86% | 228% |
| Dividend per Share 2 | 180.0 | 180.0 | 180.0 | 180.0 | 180.0 | 188.0 | 189.9 | 192.9 |
| Announcement Date | 14/05/19 | 13/05/20 | 11/05/21 | 11/05/22 | 11/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: März | 2020 S1 | 2020 S2 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2026 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16,60,200 | 16,31,000 | 15,90,785 | 8,44,797 | 17,94,400 | 9,01,294 | 8,73,289 | 9,72,465 | 10,02,340 | 19,74,800 | 10,96,551 | 9,56,200 | 10,58,618 | 10,43,089 | 21,01,707 | 11,11,200 | 8,99,902 | 10,38,000 | 10,44,000 | 20,34,000 | 11,06,000 | 9,59,000 | 20,60,000 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | 2,49,972 | 3,40,072 | 1,33,355 | - | 2,91,975 | 2,07,900 | - | - | - | - | - | - |
| EBIT 1 | 50,300 | 50,100 | 2,15,588 | 97,448 | 3,46,000 | 1,16,484 | -1,619 | 1,50,515 | 1,04,485 | 2,55,000 | 1,46,990 | 88,600 | 1,68,571 | -49,341 | 1,19,230 | 1,04,900 | 50,750 | 94,000 | - | 1,85,500 | - | - | 2,10,500 |
| Operating Margin | 3.03% | 3.07% | 13.55% | 11.54% | 19.28% | 12.92% | -0.19% | 15.48% | 10.42% | 12.91% | 13.4% | 9.27% | 15.92% | -4.73% | 5.67% | 9.44% | 5.64% | 9.06% | - | 9.12% | - | - | 10.22% |
| Earnings before Tax (EBT) 1 | -27,557 | -33,197 | 1,25,561 | 61,447 | 2,84,425 | 72,193 | -54,047 | 1,55,473 | 64,549 | 2,20,022 | 1,07,153 | 47,900 | 1,35,033 | -95,980 | 39,053 | 61,300 | 18,376 | 42,500 | - | 92,500 | - | - | 1,27,500 |
| Net income 1 | 33,200 | 11,000 | 86,548 | -16,778 | 1,83,600 | 57,769 | -11,358 | 1,05,014 | 61,786 | 1,66,800 | 1,19,127 | 31,100 | 89,395 | -48,030 | 41,365 | 1,05,700 | -18,644 | 32,500 | - | 70,500 | - | - | 97,500 |
| Net margin | 2% | 0.67% | 5.44% | -1.99% | 10.23% | 6.41% | -1.3% | 10.8% | 6.16% | 8.45% | 10.86% | 3.25% | 8.44% | -4.6% | 1.97% | 9.51% | -2.07% | 3.13% | - | 3.47% | - | - | 4.73% |
| EPS 2 | 21.00 | - | 55.45 | -10.27 | 117.0 | 37.01 | -6.950 | 67.94 | 40.06 | 108.0 | 76.70 | 20.03 | 57.51 | -31.00 | 26.51 | 67.38 | 0.7722 | 20.70 | - | 44.90 | - | - | 62.10 |
| Dividend per Share 2 | 90.00 | - | 90.00 | - | 90.00 | - | - | - | - | - | - | - | - | 94.00 | 94.00 | - | 94.00 | - | 94.00 | - | - | 94.00 | - |
| Announcement Date | 31/10/19 | 13/05/20 | 29/10/20 | 28/10/21 | 28/10/21 | 03/02/22 | 11/05/22 | 28/07/22 | 27/10/22 | 27/10/22 | 02/02/23 | 11/05/23 | 27/07/23 | 26/10/23 | 26/10/23 | 01/02/24 | - | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 50,25,582 | 44,55,690 | 36,32,551 | 34,95,716 | 38,48,811 | 37,70,713 | 34,37,808 | 31,25,679 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 10.53 x | 6.514 x | 3.398 x | 3.348 x | 3.333 x | 3.604 x | 3.132 x | 2.71 x |
| Free Cash Flow 1 | -25,07,219 | 9,61,871 | 6,17,401 | 9,99,853 | 3,70,054 | 3,44,948 | 6,75,738 | 6,64,805 |
| ROE (net income / shareholders' equity) | 3% | 0.9% | 7.6% | 4.2% | 5.3% | 2.13% | 3.88% | 4.76% |
| ROA (Net income/ Total Assets) | 1.06% | -0.46% | 2.85% | 2.32% | 2.76% | 1.03% | 1.94% | 2.52% |
| Assets 1 | 1,03,34,963 | -97,10,018 | 1,32,09,937 | 99,18,859 | 1,14,67,260 | 1,29,97,037 | 1,20,85,642 | 1,15,83,413 |
| Book Value Per Share 2 | 3,319 | 3,032 | 3,309 | 3,666 | 4,087 | 4,052 | 4,003 | 4,067 |
| Cash Flow per Share 2 | 397.0 | 403.0 | 599.0 | 520.0 | 632.0 | 704.0 | 660.0 | 676.0 |
| Capex 1 | 1,34,114 | 2,17,710 | 2,36,468 | 1,86,037 | 6,33,689 | 5,16,170 | 3,66,694 | 3,71,598 |
| Capex / Sales | 6.39% | 6.61% | 7.39% | 5.21% | 15.73% | 12.59% | 9.1% | 9.05% |
| Announcement Date | 14/05/19 | 13/05/20 | 11/05/21 | 11/05/22 | 11/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,089
JPY
Average target price
4,779
JPY
Spread / Average Target
+16.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.86% | 40.76B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4502 Stock
- Financials Takeda Pharmaceutical Company Limited
